Contents
The European Medicines Agency (EMA) released a report on the Johnson & Johnson vaccine on Tuesday. We read in it that there is a possible link between this preparation and very rare cases of atypical blood clots. The EMA began research on the vaccine after several cases of post-vaccination thrombosis occurred in the US.
- Of the more than 7 million people vaccinated with Johnson & Johnson, eight cases of blood clots have occurred
- On April 13, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) recommended that the administration of the vaccine be suspended
- Now the European Medicines Agency has informed about the results of the research. In her view, there was a possible link between Johnson & Johnson and very rare cases of unusual blood clots
- But the overall benefits of the J&J vaccine in preventing COVID-19 outweigh the risks of side effects, emphasizes EMA
- You can find more such stories on the TvoiLokony home page
The European Medicines Agency on the Johnson & Johnson vaccine
“At its meeting on April 20, 2021, the EMA Safety Committee (PRAC) concluded that a warning about unusual blood clots with low platelet counts should be added to the product information of Janssen COVID-19 (manufactured by Johnson & Johnson). The PRAC also concluded that these events should be mentioned as very rare side effects of the vaccine, ”reads a statement from the European Medicines Agency.
“The committee took into account all the evidence currently available, including eight reports from the United States of serious cases of atypical blood clots associated with low platelet levels, one of which has been fatal. By April 13, 2021, more than 7 million people had received the Janssen vaccine in the United States.
All cases occurred in people under 60 years of age in the three weeks following vaccination, the majority in women. Based on the evidence currently available, no specific risk factors have been confirmed, »informs EMA.
“One of the likely explanations for the combination of blood clots and low platelet counts is an immune response leading to a condition similar to what is sometimes seen in patients treated with heparin called post-heparin thrombocytopenia (HIT),” the Agency explains.
The benefits of the Johnson & Johnson vaccine outweigh the risk of side effects
The EMA Safety Committee noted in a statement that blood clots after vaccination with Johnson & Johnson mainly occurred in atypical sites such as the veins in the brain (cerebral venous sinus thrombosis, CVST) and abdomen (splanchnic vein thrombosis) and in the arteries. along with low blood platelet counts and sometimes bleeding.
The cases analyzed were very similar to those that occurred with the COVID-19 vaccine developed by AstraZeneca – Vaxzevria.
- Johnson & Johnson Vaccine: Benefits Outweigh Risks of Side Effects
The European Medicines Agency, as before with AstraZeneca, highlighted that COVID-19 is associated with a risk of hospitalization and death, and that the reported combination of blood clots and low platelet counts is very rare. Therefore, the overall benefits of the COVID-19 Janssen vaccine in preventing COVID-19 outweigh the risks of side effects.
Johnson & Johnson Vaccine and Blood Clots
The EMA announced Friday, April 9, that the study of blood clots in people given the Johnson & Johnson vaccine had begun. Until then, four such cases had been reported in the US.
On Tuesday, April 13, the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) recommended that J&J be suspended due to six cases of blood clots among 6,8 million vaccinated people.
- Which countries are winning the fight against COVID-19? Where is Poland located? Latest ranking
Today’s EMA Security Committee report finally lists eight such cases.
Johnson & Johnson vaccine in Poland
Johnson & Johnson vaccine is currently only used in the US. It was authorized in the EU on March 11, 2021, but vaccination with it has not yet started in any EU country.
The EU placed an order for 200 million doses of this vaccine, with an option for an additional 200 million doses. In mid-March, the President of the European Commission, Ursula von der Leyen, announced that EU countries should receive in the second quarter of this year. approximately 55 million doses of the preparation.
- Johnson & Johnson COVID-19 vaccine. The most important information
The first delivery of the Johnson & Johnson vaccine to Poland, containing 120 thousand. doses arrived on April 14. In total, we are to receive 16,9 million units.
Johnson & Johnson is a vector vaccine (like AstraZeneca). It is based on the use of fragments of other viruses to trigger an immune response against a specific virus – in this case, the SARS-COV-2 coronavirus. Unlike other preparations that have been approved for use in the European Union, the Johnson & Johnson vaccine is single-dose. Its effectiveness is 66 percent.
You may be interested in:
- More than 3 million people have died worldwide from COVID-19. There may be more victims
- Who Dies More Of COVID-19? Gender can be crucial
- What’s next for the Polish health care system? Doctors have grim scenarios
The content of the medTvoiLokony website is intended to improve, not replace, the contact between the Website User and their doctor. The website is intended for informational and educational purposes only. Before following the specialist knowledge, in particular medical advice, contained on our Website, you must consult a doctor. The Administrator does not bear any consequences resulting from the use of information contained on the Website. Do you need a medical consultation or an e-prescription? Go to halodoctor.pl, where you will get online help – quickly, safely and without leaving your home.Now you can use e-consultation also free of charge under the National Health Fund.